49O Clinical experience of tabelecleucel in Epistein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) involving the central nervous system
Year: 2023
Type: article
Abstract: Tabelecleucel is an investigational, off-the-shelf, allogeneic EBV-specific T-cell immunotherapy being studied in patients (pts) with EBV+ diseases, including EBV+ PTLD with central nervous system (CNS) involvement. Pts with relapsed/refractory (R/R) EBV+ CNS PTLD have very limited treatment options and poor prognosis. We previously reported results from pts with R/R EBV+ CNS PTLD treated within 2 single-center studies. We report here a combined analysis from 4 open-label studies.
Source: Immuno-Oncology Technology
Authors: R. Baiocchi, S. Choquet, M. Ghosh, E. Orciuolo, J. Patton, R. Dinavahi, J. Wahlstrom, X. You, S. Zhang, S. Prockop
Institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Pitié-Salpêtrière Hospital, University of Michigan, Michigan Medicine, University of Pisa, Atara Biotherapeutics (United States), Boston Children's Hospital, Dana-Farber Cancer Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,020
Funder: Atara Biotherapeutics
OpenAlex ID: W4389480926